Laurus Labs Ltd

Laurus Labs Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Laurus Labs Ltd

₹ 594 0.20%
13 May 12:51 p.m.
lauruslabs.com BSE: 540222 NSE: LAURUSLABS
About

Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company having a global leadership
position in select Active Pharmaceutical Ingredients (APIs) including anti-retroviral, oncology drugs (incl High Potent APIs), Cardiovascular, and Gastro therapeutics. They also offer integrated CMO and CDMO services to Global Innovators from Clinical phase drug development to commercial manufacturing.
Laurus employs 6500+ people, including around 1050+ scientists at more than 11 facilities approved by global agencies USFDA, WHO-Geneva, Japan-PDMA, UK-MHRA, EMA, TGA etc. [1]

Key Points

Business Segments
1) Generic API (46% in 9M FY25 vs 41% in FY22): [1] [2] The company has one of the largest HiPotent API manufacturing capacities in India and is the world's leading third-party supplier of antiretroviral APIs. Its portfolio includes antiretrovirals, oncology, steroids, hormones, and cardiovascular APIs, serving global generic pharmaceutical companies. Segment revenue declined by 3% YoY in 9M FY25 due to ARV capacity reallocation towards high-yield, long-term business opportunities. [3] [1]

Website BSE NSE
  • Market Cap ₹ 32,037 Cr.
  • Current Price ₹ 594
  • High / Low ₹ 661 / 385
  • Stock P/E 84.2
  • Book Value ₹ 84.6
  • Dividend Yield 0.20 %
  • ROCE 10.4 %
  • ROE 8.67 %
  • Face Value ₹ 2.00
Edit ratios

Pros

Cons

  • Stock is trading at 7.11 times its book value
  • Company has a low return on equity of 11.2% over last 3 years.
  • Dividend payout has been low at 14.9% of profits over last 3 years

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Part of Nifty Smallcap 100 Nifty 500 Nifty Pharma BSE Allcap BSE 250 SmallCap Index

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
1,378 1,495 1,498 1,501 1,279 1,108 1,158 1,132 1,415 1,117 1,185 1,265 1,650
1,005 1,077 1,072 1,116 1,027 980 978 962 1,143 956 1,003 1,059 1,255
Operating Profit 373 418 426 385 252 128 181 170 271 161 182 206 395
OPM % 27% 28% 28% 26% 20% 12% 16% 15% 19% 14% 15% 16% 24%
2 3 4 3 6 7 6 11 24 9 12 7 72
Interest 29 28 38 39 41 33 38 38 42 41 45 48 49
Depreciation 61 66 76 78 81 84 85 87 89 91 91 89 88
Profit before tax 285 328 317 270 137 17 63 57 164 39 58 77 330
Tax % 22% 29% 28% 26% 25% 24% 26% 25% 26% 26% 27% 25% 24%
221 232 227 199 102 13 47 43 121 29 42 57 252
EPS in Rs 4.12 4.31 4.23 3.70 1.90 0.24 0.87 0.79 2.25 0.53 0.79 1.06 4.67
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
1,160 1,326 1,775 1,892 2,027 2,236 2,797 4,769 4,707 5,773 4,812 5,217
951 1,121 1,402 1,478 1,618 1,884 2,226 3,258 3,421 4,292 4,062 4,273
Operating Profit 209 205 372 414 409 352 571 1,511 1,286 1,482 751 944
OPM % 18% 15% 21% 22% 20% 16% 20% 32% 27% 26% 16% 18%
9 34 4 32 28 15 5 26 20 16 47 100
Interest 64 106 111 97 75 86 88 66 96 146 151 182
Depreciation 33 61 86 104 121 161 184 197 235 301 345 359
Profit before tax 121 72 180 245 241 121 304 1,275 975 1,051 301 504
Tax % 20% -2% 19% 18% 28% 22% 12% 25% 23% 28% 26% 24%
97 74 145 200 173 95 267 956 750 760 224 380
EPS in Rs 12.64 9.47 18.36 3.78 3.27 1.78 5.00 17.82 13.96 14.12 4.15 7.05
Dividend Payout % 0% 0% 2% 8% 9% 17% 10% 11% 14% 14% 19% 11%
Compounded Sales Growth
10 Years: 15%
5 Years: 13%
3 Years: 3%
TTM: 8%
Compounded Profit Growth
10 Years: 18%
5 Years: 7%
3 Years: -20%
TTM: 70%
Stock Price CAGR
10 Years: %
5 Years: 47%
3 Years: 3%
1 Year: 37%
Return on Equity
10 Years: 16%
5 Years: 18%
3 Years: 11%
Last Year: 9%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 15 16 16 106 106 106 107 107 107 108 108 108
Reserves 281 645 790 1,250 1,407 1,484 1,709 2,605 3,281 3,949 4,099 4,456
605 888 1,081 808 947 1,009 1,051 1,411 1,653 1,714 2,110 2,380
372 344 342 509 547 718 872 1,502 1,567 1,187 1,351 1,643
Total Liabilities 1,273 1,893 2,229 2,673 3,008 3,318 3,739 5,625 6,609 6,958 7,667 8,587
499 801 1,014 1,193 1,448 1,599 1,694 1,818 2,186 2,884 3,036 2,888
CWIP 116 107 70 143 163 107 67 324 755 357 156 336
Investments 0 19 26 51 52 58 58 319 362 384 635 740
658 966 1,119 1,286 1,345 1,554 1,920 3,164 3,306 3,333 3,841 4,623
Total Assets 1,273 1,893 2,229 2,673 3,008 3,318 3,739 5,625 6,609 6,958 7,667 8,587

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
121 -59 197 321 369 293 345 694 823 882 659 540
-312 -406 -315 -282 -417 -257 -217 -900 -837 -735 -757 -592
203 486 90 -47 49 -37 -127 243 15 -185 139 59
Net Cash Flow 12 21 -27 -8 0 -0 0 38 2 -39 41 8

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 61 78 91 108 100 112 102 98 98 94 124 142
Inventory Days 165 210 177 184 199 201 233 257 279 211 258 258
Days Payable 114 101 91 110 106 144 157 194 140 90 151 138
Cash Conversion Cycle 112 187 177 183 193 169 177 161 237 216 231 262
Working Capital Days 48 119 117 126 124 116 119 127 140 138 175 190
ROCE % 25% 15% 17% 17% 14% 8% 14% 38% 23% 22% 8% 10%

Shareholding Pattern

Numbers in percentages

Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025
27.27% 27.27% 27.20% 27.20% 27.20% 27.20% 27.18% 27.18% 27.18% 27.18% 27.62% 27.62%
21.98% 22.67% 21.90% 22.42% 22.52% 24.03% 25.39% 25.98% 25.67% 26.08% 25.56% 25.51%
9.11% 9.34% 9.51% 9.74% 10.36% 11.01% 11.13% 11.78% 13.56% 13.05% 12.74% 11.78%
41.65% 40.74% 41.38% 40.64% 39.93% 37.75% 36.30% 35.07% 33.59% 33.69% 34.09% 35.09%
No. of Shareholders 4,07,1863,90,6954,23,9314,18,6154,17,9774,02,6403,82,8803,56,8303,24,0593,09,0632,92,2142,92,905

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls